About ETS domain-containing protein Elk-3
ETS domain-containing protein Elk-3 (ELK3) is a protein
from Homo sapiens identified by UniProt accession
P41970, 407 residues long.
MolForge cross-references it against 0 known binders and
81 disease associations.
Target properties
| Protein name | ETS domain-containing protein Elk-3 |
| UniProt accession | P41970 |
| Gene | ELK3 |
| Organism | Homo sapiens |
| Length | 407 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (81)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.44
- cortical surface area measurement · score 0.40
- body height · score 0.34
- brain measurement · score 0.32
- B-cell acute lymphoblastic leukemia · score 0.31
- lymphocyte count · score 0.27
- neurofibrillary tangles measurement · score 0.23
- small intestine neuroendocrine tumor · score 0.20
- FEV/FVC ratio · score 0.14
- arterial stiffness measurement · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P41970-F1 | alphafold | PREDICTED | 59.36 | — |
Amino-acid sequence (407 residues)
MESAITLWQF LLQLLLDQKH EHLICWTSND GEFKLLKAEE VAKLWGLRKN KTNMNYDKLS RALRYYYDKN IIKKVIGQKF VYKFVSFPEI LKMDPHAVEI SRESLLLQDS DCKASPEGRE AHKHGLAALR STSRNEYIHS GLYSSFTINS LQNPPDAFKA IKTEKLEEPP EDSPPVEEVR TVIRFVTNKT DKHVTRPVVS LPSTSEAAAA SAFLASSVSA KISSLMLPNA ASISSASPFS SRSPSLSPNS PLPSEHRSLF LEAACHDSDS LEPLNLSSGS KTKSPSLPPK AKKPKGLEIS APPLVLSGTD IGSIALNSPA LPSGSLTPAF FTAQTPNGLL LTPSPLLSSI HFWSSLSPVA PLSPARLQGP STLFQFPTLL NGHMPVPIPS LDRAASPVLL SSNSQKS
Explore ETS domain-containing protein Elk-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets